ReviewTherapeutic advances in medical oncology2020
Current management of
Review in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- High-dose alectinib forContemporary oncology (Poznan, Poland) · 2023Trial
- Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer.Translational oncology · 2026Article
- RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.International journal of molecular sciences · 2026Review
- Changing profile of lung cancer clinical characteristics in China: Over 8-year population-based study.Chinese medical journal pulmonary and critical care medicine · 2023Article
- RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.The oncologist · 2023Review
- Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer.Pharmaceutics · 2023Review
- Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.International journal of molecular sciences · 2023Review
- Management of Combined Therapy (Ceritinib,Life (Basel, Switzerland) · 2022Article
- Pralsetinib treatment for multipleThe Journal of international medical research · 2022Article
- Clinicopathologic characteristics and diagnostic methods ofTranslational lung cancer research · 2022Article
- Multicenter real-world data of patients harboring rare mutations other than EGFR or ALK in advanced or metastatic non-small cell lung cancer.Thoracic cancer · 2022Article
- Efficacy and safety of selpercatinib in Chinese patients with advancedTherapeutic advances in medical oncology · 2022Article
- The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research.Frontiers in oncology · 2022Article
- Emerging genetic biomarkers in lung adenocarcinoma.SAGE open medicine · 2022Review
- Targeted therapy of RET fusion-positive non-small cell lung cancer.Frontiers in oncology · 2022Review
- Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.Cancer science · 2022Article
- Circular RNA circDNA2 upregulatesMolecular therapy. Nucleic acids · 2021Article
- Association between somatic RET mutations and clinical and genetic characteristics in patients with metastatic colorectal cancer.Cancer medicine · 2021Article
- Therapeutic strategies in RET gene rearranged non-small cell lung cancer.Journal of hematology & oncology · 2021Review
- A narrative review of MET inhibitors in non-small cell lung cancer withTranslational lung cancer research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of oncogenic drivers, and the subsequent development of targeted therapies established biomarker-based care for metastatic non-small cell lung cancer (NSCLC). Biomarker testing is standard of care in NSCLC patients with adenocarcinoma because multiple targeted therapies are available. Rearranged during transfection (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.